The two-dimensional electrophoretic method with silver staining we describe better resolves plasma apolipoproteins (apo) than any procedure previously described. It can be usedto screenfor abnormalitiesin apoA-l, apoA-lI, apoA-IV, apoC-lI, apoC-Ill, apoD, apoE, and apoH. In addition,this is the first presentation of apoD and apoH on two-dimensional gels. This electrophoretic method will permit the quantification of plasma apolipoproteins by computer imaging. Such detailed analysis of the plasma apolipoproteinsshouldprovide a better understandingof apolipoproteinfunction and the role these apolipoproteinsplay in lipoproteinmetabolism and the pathophysiology of dyslipoproteinemias and coronary artery disease. Inconsistency and lack of a standardized nomenclature for the plasma apolipoproteins have resulted in confusion in the literature. Therefore, we have adopted a nomenclature for the apolipoproteins that is consistent with the nomenclature currently standardized for identification of proteins separated by two-dimensional electrophoresis (9-11).
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The two-dimensional electrophoretic method with silver staining we describe better resolves plasma apolipoproteins (apo) than any procedure previously described. It can be usedto screenfor abnormalitiesin apoA-l, apoA-lI, apoA-IV, apoC-lI, apoC-Ill, apoD, apoE, and apoH. In addition,this is the first presentation of apoD and apoH on two-dimensional gels. This electrophoretic method will permit the quantifica- Structural defects in the plasma apolipoproteins may affect either the charge or the molecular mass of the protein. Two-dimensional electrophoresis, which characterizes proteins by both of these characteristics, may be used to identify up to 30% of the known amino acid substitutions (5).
The purpose of this study is to present a relatively simple two-dimensional electrophoretic method for evaluating plasma apolipoproteins
A-I (apoA-I), A-il, A-N, C-il, C-rn, D, E,
and H.' In addition, apoC-I may be evaluated by using an extended pH range and apoB-48 as well as apoB-100 by use of 3% polyacrylamide SDS gel electrophoresis. We find this Molecular Disease Branch, National Heart, Lung, and Blood Inconsistency and lack of a standardized nomenclature for the plasma apolipoproteins have resulted in confusion in the literature. Therefore, we have adopted a nomenclature for the apolipoproteins that is consistent with the nomenclature currently standardized for identification of proteins separated by two-dimensional electrophoresis (9-11).
Materials and Methods

Samples.
Blood was collected in tubes containing
Na2EDTA
(final concentration, about 1 gIL) as anticoagulant. The erythrocytes were removed and the plasma was stored at 4 #{176}C for as long as two weeks before analysis.
For two-dimensional electrophoresis
we used plasma or isolated lymph chylomicrons, VLDL, and HDL. Human thoracic duct lymph was collected and chylomicrons were separated by centrifugation in an SW 27 Beckman swinging-bucket rotor for 115 mm at 25000 rpm and 4#{176}C. VLDL was isolated by ultracentrifugation (12) of 5 mL of plasma in a 40.3 Beckman rotor (Beckman Instrument Co., Fullerton, CA) at 39000 rpm ( 110 000 x g) at 4#{176}C for 18 h. HDL was isolated by ultracentrifugation between relative densities of 1.063 to 1.21 (4 #{176}C, 36 h, 39 000 rpm). The pH was adjusted to 5.0 with HC1 and the mixture was incubated at 37 #{176}C for 4 h. We then added 4 L of this solution to 10 L of the detergent solution, followed by 9 mg of solid urea. Immunoblotting was performed as previously described (19). Plasma gels were blotted at 80 V for 1 h onto nitrocellulose sheets. Isolation of antibodies to apoA-ll and apoD has been previously reported (20, 21) . Second antibody was used as described in manufacturer's (Bio-Rad Lab.) instructions. Table 1 lists the major human plasma apolipoproteins and some of their physico-chemical properties. Figure 1 shows a gel on which the human plasma apolipoproteins are re- A-Il aDesi gnatedwith zero subscript in text.
Results
b Dimer.
CApe;
also has been reported as ApoE-3 (see text).
solved by use of a narrow pH range (4.0-7.0). Figure 2 illustrates an electrophoretogram for a sample preincubated with neuraminidase (EC 3.2.1.18). ApoB does not appear on these gels, owing to its high molecular mass, nor does apoC-I, whose p1 is outside the 4-7 pH range. Mature apoA-I is polymorphic in plasma (Figure 1) . The major isoform in plasma, designated apoA-L3, has been previously designated in the literature as apoA-I3 (26), apoA-14 (7), or apoA-I1 (31). ApoA-I+2 in plasma and lymph is proapoA-I ( Figure 6 ) (26). The minor isoforms at apoA-I+1 and apoA-L1 are primarily de-amidated proapoA-I and mature apoA-I, respectively.
Several apoA-I variants have now been recognized. The most extensively studied is apoA-ITa,,er (32,33), characterized by a marked increase in apoA-I+2 or proapoA-Ij0 (Figure 6 ). Several additional apoA-I variants identified by two-dimensional electrophoresis are summarized in Table 2 (31,34-36). 
ApoA-I variants
ApoA-ll
ApoA-H, the second major protein of HDL, is biosynthesized as a 100-residue precursor protein, preproapoA-ll (37). PreproapoA-II is co-translationally cleaved to proapoA-II, which contains a pentapeptide attached to mature apoA-ll (38). 
ApoA-IV
ApoA-IV, a 393-residue protein, Mr 46 000, is present on triglyceride-rich lipoproteins and may be involved in their metabolism (44, 45).
ApoA-IV has been provisionally assigned to chromosome 11(46). The major apoA-W isoform,
. w . (Table 3) .
ApoB
Human apoB can be separated into two forms, apoB-48 and apoB-100, which are synthesized by the intestine and liver, respectively Figure 1 because its p1 is 8.0. Figure 10 , which shows a gel in which a pH range of 6 to 9 was used, illustrates the relative positions of apoC-I and apoA-I. ApoC-I appears to have two isoforms.
ApoC-Il
ApoC-il is a 79-residue apolipoprotein that functions as a co-factor for lipoprotein lipase, the major enzyme catalyzing the hydrolysis of plasma triglycerides (57, 58). ApoC-il is synthesized as a 101-residue precursor, preapoC-il (59), which undergoes co-translational cleavage to mature apoC-
11(60,61).
ApoC-il has been localizedto chromosome 19(62,
63).
The major apoC-il isoform, apoC-110, has a p1 of 4.7.
Although a minor isoform (demonstrated here as apoC-111) has been reported (64), it has not been consistently identified on the plasma electrophoretogranis (Figures 1, 11) .
Immunoblot techniques
have further identified two other isoforms for apoC-il, illustrated in Figures 3 and 4 .
Patients with a deficiency of apoC-il are characterized clinically by supranormal triglyceride concentrations in their plasma and a type I hyperlipoproteinemia (65, 67) . 
ApoC-Ill
ApoC-ilI is synthesized as a 99-residue protein, preapoC-111(68). This is co-translationally cleaved to yield mature apoC-ifi, which is present in plasma as three isoforms containing no, one, or two neuraminic acid residues. The major desialylated isoform, apoC-fflo, is a minor isoform in plasma. The two predominant isoforms, apoC-ffl..1 and apoC-ffl_2, contain one and two sialic acid residues, respectively (69) (Figure 11) . The p1 of the apoC-fflo, apoC-IIL..1, and apoC-ffi_2 isoforms are 4.9, 4.65, and 4.5, respectively. Restriction enzyme analysis of the genomic DNA of a second kindred with apoA-I+apoC-ffl deficiency has shown no major deletions or insertions in either the apoA-I or apoC-ifi gene (72 Figure  12 ). The major isoform of desialylated apoD, apoDo, has a p1 of 5.3 (Figure 2 ). The electrophoretic relationship of apoA-I, apoA-fl, and apeD, as evaluated by the immunoblot technique, is illustrated in Figure 12 . 
ApoE
ApoE, a 299-residue glycoprotein, is synthesized as an amino acid precursor protein, preapoE (76, 77) . PreapoE undergoes co-translational cleavage of the 18-residue prepeptide to mature apoE, which is secreted into plasma as a sialylated apolipoprotein. Newly secreted sialylated apoE loses the sialic acid residues, and the predominant apoE isoforms in plasma contain no sialic acid (Figures 1 and 2 ).
ApoE is located at a single genetic locus, and there are three The common apoE isoforms differ at two positions in the amino acid sequence (i.e., positions 112 and 158), apoE-2 containing Cys 112 and Cys 158, apoE-3 Cys 112 and Arg f58, and apoE-4 Arg 112 and Arg 158. The most common allele, #{128}3, is considered to be a normal allele. The locus for apoE may be located on human chromosome 19 (78) .
ApoE is also considered important in the metabolism of triglyceride-rich lipoproteins and to bind in vitro to a specific membrane receptor in the liver (79 A recently identified kindred with phenotype E1/3 is also presented (Figure 13 ). The nomenclature of apoE has been confusing and has recently been reviewed (6). In the present report, we locate apoE-3, the predominant normal plasma isoform, at the designatedapoEoposition, for consistency with the nomen-
E3/4
Phenotype E1/3 Phenotype
clature for proteins separated by two-dimensional electrophoresis. The other two major isoforms, apoE-2 and apoE-4 are located at positions designated apoE1 and apoE+1, respectively.
However, the previous apoE-2, apoE-3, and apoE-4 designations are also included in parentheses in the two-dimensional electrophoretograms in Figure 12 
Treatment
of apoH with neuraminidase shifts the electrophoretic position of apoH to a p1 = 9.5 (Figure 14) . Desialylated apoH is not visible on the electrophoretogram in Figure 2 because of the narrow pH range.
Discussion
The analytical system we describe is sensitive and reproducible for evaluating apolipoproteins in normal subjects and patients with dyslipoproteinemias. The desialylated form has a p1 = 9.5 ly important in apoE-apoA-ll dimers and apoE-apoE dimere.) Reduction of the sample also significantly increases the quantity of monomer apoA-ll and apoE.
In the present study, we identified two new proteins on theplasma two-dimensional gel electrophoretograms: apoD and apoH. Both are glycoproteins, with many polymorphic isoforms present. Most of the isoforms are eliminated by treatment with neuraminidase.
Use of computerized gel-image systems for apolipoprotein quantification will provide additional information on plasma apolipoprotein concentrations and isoform distribution in normal subjects and patients with dyslipoproteinemias. This quantification technique is currently under investigation.
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